Abstract
Evaluation of: Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. DOI: 10.1200/JCO.2010.33.2312 (Epub ahead of print) (2011).
Melanoma is a deadly skin disease well known for resistance to chemotherapies and immunomodulating therapies. PLX4032 is a selective BRAF inhibitor and, in clinical trials, has consistently induced tumor responses in the majority of patients with BRAF V600E mutant melanoma. However, duration of response has been limited due to the development of acquired resistance. This article evaluates a recently published investigation evaluating the resistant mechanisms to BRAF therapy using tumor genomic profiling of isolated DNA from responsive and acquired resistant melanoma tissue in a patient treated with the BRAF inhibitor PLX4032.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.